Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma.

[1]  Yang Zhang,et al.  Combined p53‐related genetic variants together with HPV infection increase oral cancer risk , 2012, International journal of cancer.

[2]  A. Jemal,et al.  Cancers with increasing incidence trends in the United States: 1999 through 2008 , 2012, CA: a cancer journal for clinicians.

[3]  Q. Wei,et al.  Association of BRCA1 functional single nucleotide polymorphisms with risk of differentiated thyroid carcinoma. , 2012, Thyroid : official journal of the American Thyroid Association.

[4]  Caitlin P. McHugh,et al.  Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. , 2011, Human molecular genetics.

[5]  M. Russo,et al.  Overexpression of estrogen receptor‐α in human papillary thyroid carcinomas studied by laser‐capture microdissection and molecular biology , 2011, Cancer science.

[6]  Q. Wei,et al.  Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck , 2011, Molecular carcinogenesis.

[7]  J. Bai,et al.  MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis. , 2011, Journal of genetics and genomics = Yi chuan xue bao.

[8]  Q. Wei,et al.  p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck , 2011, Cancer.

[9]  E. Brambilla,et al.  The ARF tumor suppressor: Structure, functions and status in cancer , 2010, International journal of cancer.

[10]  James Allan,et al.  Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk , 2010, Nature Genetics.

[11]  Yuri E Nikiforov,et al.  Molecular diagnostics and predictors in thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[12]  E. Sturgis,et al.  Molecular epidemiology of papillary thyroid cancer: in search of common genetic associations. , 2009, Thyroid : official journal of the American Thyroid Association.

[13]  O. Soldin,et al.  Thyroid hormone levels associated with active and passive cigarette smoking. , 2009, Thyroid : official journal of the American Thyroid Association.

[14]  Q. Wei,et al.  Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case-control analysis. , 2009, Thyroid : official journal of the American Thyroid Association.

[15]  Q. Wei,et al.  A Novel Functional Polymorphism C1797G in the MDM2 Promoter Is Associated with Risk of Bladder Cancer in a Chinese Population , 2008, Clinical Cancer Research.

[16]  H. Schünemann,et al.  Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties , 2008, Journal of Molecular Medicine.

[17]  K. Vousden,et al.  Coping with stress: multiple ways to activate p53 , 2007, Oncogene.

[18]  C. Larsen,et al.  The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression , 2006, British Journal of Cancer.

[19]  M. Spitz,et al.  MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. , 2006, Carcinogenesis.

[20]  A. Levine,et al.  MDM2 SNP309 accelerates colorectal tumour formation in women , 2006, Journal of Medical Genetics.

[21]  A. Levine,et al.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.

[22]  E. Brambilla,et al.  p14ARF Triggers G2 Arrest Through ERK-Mediated Cdc25C Phosphorylation, Ubiquitination and Proteasomal Degradation , 2006, Cell cycle.

[23]  Wen Tan,et al.  Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer , 2006, Human mutation.

[24]  Asif J. Chaudhry,et al.  Ras-Raf-Arf Signaling Critically Depends on the Dmp1 Transcription Factor , 2005, Molecular and Cellular Biology.

[25]  Nicoleta C. Arva,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[26]  Timothy R. Rebbeck,et al.  Assessing the function of genetic variants in candidate gene association studies , 2004, Nature Reviews Genetics.

[27]  Guillermina Lozano,et al.  MDM2, an introduction. , 2003, Molecular cancer research : MCR.

[28]  H. Kinyamu,et al.  Estrogen Receptor-Dependent Proteasomal Degradation of the Glucocorticoid Receptor Is Coupled to an Increase in Mdm2 Protein Expression , 2003, Molecular and Cellular Biology.

[29]  M. Zou,et al.  Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. , 2001, Molecular genetics and metabolism.

[30]  S. Horie,et al.  Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features , 2001, Pathology international.

[31]  F. McCormick,et al.  Opposing Effects of Ras on p53 Transcriptional Activation of mdm2 and Induction of p19ARF , 2000, Cell.

[32]  N. Kreiger,et al.  Cigarette smoking and the risk of thyroid cancer. , 2000, European journal of cancer.

[33]  M. Serrano,et al.  p19ARF links the tumour suppressor p53 to Ras , 1998, Nature.

[34]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[35]  J H Lubin,et al.  Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. , 1995, Radiation research.

[36]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[37]  C. Ishioka,et al.  Locus-specific mutation databases: pitfalls and good practice based on the p53 experience , 2006, Nature Reviews Cancer.

[38]  A. Levine,et al.  Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.